Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting
Effective for claims with dates of service on and after December 9, 2009, contractors shall be aware that percutaneous transluminal angioplasty (PTA) concurrent with carotid artery stenting (CAS) system placement in Food and Drug Administration-Approved post-approval studies, and PTA
Concurrent with CAS system placement in patients at high risk for carotid endarterectomy includes revised language specific to embolic protection devices. See Pub. 100-03, section 20.7 for detailed information in this
regard
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: March 05, 2010
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.